A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Key facts

Sponsor

Peter MacCallum Cancer Centre, Australia

Principal Investigator

Michael Dickinson

Peter MacCallum Cancer Centre & Royal Melbourne Hospital

Intervention

Rituximab(drug)

Enrollment

80 enrolled

Eligibility

18-65 years · All sexes

Timeline

2021 – 2025

Study locations (15)

• Concord Repatriation General Hospital, Camperdown, New South Wales, Australia
• St Vincent's Public Hospital Sydney, Darlinghurst, New South Wales, Australia
• Calvary Mater Newcastle, Newcastle, New South Wales, Australia
• Prince of Wales Hospital, Randwick, New South Wales, Australia
• Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
• Princess Alexander Hospital, Woolloongabba, Queensland, Australia
• Royal Adelaide Hospital, Adelaide, South Australia, Australia
• Box Hill Hospital, Box Hill, Victoria, Australia
• Barwon Health, Geelong, Victoria, Australia
• Cabrini Hospital, Malvern, Victoria, Australia
• Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
• St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
• Alfred Hospital, Melbourne, Victoria, Australia
• Epworth Healthcare, Melbourne, Victoria, Australia
• Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

Collaborators

Hoffmann-La Roche

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →